Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Ryzneuta Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0745

    Colony Stimulating Factors - Ryzneuta

    Customize your policy alerts

    Sign up for Cigna Policy IP0745 alerts

    Get alerted when Policy IP0745 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage of Ryzneuta for adults with non-myeloid malignancies receiving myelosuppressive chemotherapy and for hematopoietic acute radiation syndrome, including prior authorization, clinical criteria, dosing, specialist prescribing, preferred-product requirements, and noncovered uses.

    Policy Summary
    PayerCigna
    PolicyColony Stimulating Factors - Ryzneuta
    Policy CodePolicy IP0745
    Change TypeNo material clinical or coverage change
    Effective DateNovember 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document that the applicable clinical criteria and dosing requirements are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥20%High febrile-neutropenia risk
    6 monthsCancer approval duration
    20 mg/2 weeksChemotherapy dose limit
    1 monthH-ARS approval duration
    2 doses

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    H-ARS dosing limit
    J9361Covered HCPCS code

    Coverage Criteria

    FDA-Approved Indication: Cancer Receiving Myelosuppressive Chemotherapy

    Covered for 6 months when ALL of the following are met:

    ALL of the following

    • Patient is ≥ 18 years of age.
    • ONE of the following

      • Patient is receiving myelosuppressive anti-cancer medications that are associated with a high risk of febrile neutropenia.≥ 20% risk based on the chemotherapy regimen
      • BOTH of the following

        • Patient is receiving myelosuppressive anti-cancer medications that are associated with a risk of febrile neutropenia.< 20% risk based on the chemotherapy regimen
        • Patient has at least ONE risk factor for febrile neutropenia according to the prescriber.

          Examples of risk factors include age > 65 years receiving full chemotherapy dose intensity; prior chemotherapy or radiation therapy; persistent neutropenia; bone marrow involvement by tumor; recent surgery and/or open wounds; liver dysfunction (bilirubin > 2.0 mg/dL); renal dysfunction (creatinine clearance < 50 mL/min); poor performance status; and HIV infection with low CD4 counts.

      • BOTH of the following

        • Patient has had a neutropenic complication from a prior chemotherapy cycle and did not receive prophylaxis with a colony stimulating factor.

          Examples of colony stimulating factors include filgrastim products, pegfilgrastim products, and Rolvedon (eflapegrastim-xnst) subcutaneous injection.

        • A reduced dose or frequency of chemotherapy may compromise treatment outcome.
    • The medication is prescribed by or in consultation with an oncologist or hematologist.
    • Preferred product criteria are met for the product(s) as listed in the applicable table(s).

      Dosing: Approve up to 20 mg by subcutaneous injection no more frequently than once every 2 weeks.

    Other Use with Supportive Evidence: Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS)

    Covered for 1 month when BOTH of the following are met:

    BOTH of the following

    • Patient is ≥ 18 years of age.
    • The medication is prescribed by or in consultation with a physician who has expertise in treating acute radiation syndrome.

      Dosing: Approve two doses of up to 20 mg by subcutaneous injection no more frequently than 1 week apart.

    Ryzneuta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

    Ryzneuta for any other use is not medically necessary, including peripheral blood progenitor cell collection and therapy. This list may not be all-inclusive; criteria will be updated as new published data become available.

    Coding and Clinical Thresholds

    Medically Necessary HCPCS CodeHCPCSCovered
    J9361Injection, efbemalenograstim alfa-vuxw, 0.5 mg
    High febrile neutropenia risk
    Risk thresholdAt least 20% risk of febrile neutropenia based on the chemotherapy regimen
    Treatment contextMyelosuppressive anticancer medications
    Qualifying indicationCancer in a patient receiving myelosuppressive chemotherapy
    Intermediate febrile neutropenia risk
    Regimen riskLess than 20% risk of febrile neutropenia based on the chemotherapy regimen
    Additional requirementAt least one risk factor for febrile neutropenia according to the prescriber

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Ryzneuta. Approval is recommended only when the applicable policy criteria and dosing limits are met; extended approval is available when the patient continues to meet those requirements.

    • Cancer with myelosuppressive chemotherapy: approval may be available for 6 months.
    • Acute radiation syndrome: approval may be available for 1 month.
    Prior Authorization

    Specialist Prescribing or Consultation Required

    Ryzneuta must be prescribed by or in consultation with a physician who specializes in the condition being treated. For cancer-related use, the prescriber or consultant must be an oncologist or hematologist; for acute radiation syndrome, the physician must have expertise in treating the condition.

    • Specialist involvement is required for both covered indications.
    • The specialist requirement supports evaluation, diagnosis, monitoring for adverse events, and assessment of long-term efficacy.

    Background

    Ryzneuta (efbemalenograstim alfa-vuxw) is a granulocyte colony-stimulating factor (G-CSF). It is used to reduce the incidence of infection manifested by febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant risk of febrile neutropenia.

    Definitions

    Ryzneuta
    ProductRyzneuta is a granulocyte colony-stimulating factor (G-CSF)
    IndicationIndicated to decrease the incidence of infection manifested by febrile neutropenia
    Eligible populationAdults with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
    Hematopoietic acute radiation syndrome
    ConditionHematopoietic acute radiation syndrome
    CauseRadiation-induced myelosuppression
    Relevant event

    Initial Therapy Criteria

    Cancer Receiving Myelosuppressive Chemotherapy

    Approve for 6 months when all cancer-indication criteria and dosing requirements are met.

    Initial cancer therapy approval

    • Adult patient

      • The patient is at least 18 years of age.≥18 years
    • Qualifying chemotherapy-risk pathway

      • High-risk regimen

        • The patient is receiving myelosuppressive anticancer medications associated with a high risk of febrile neutropenia.Risk is at least 20% based on the chemotherapy regimen

    Continuation Therapy

    Continuation Therapy

    Extended approvals are allowed when the patient continues to meet the applicable criteria and dosing requirements.

    Continuation approval

    • The patient continues to meet the applicable indication criteria, including the required age, qualifying indication, and specialist-prescribing requirements.
    • The patient continues to receive Ryzneuta according to the established dosing requirements for the applicable indication.

      For cancer receiving myelosuppressive chemotherapy: up to 20 mg subcutaneously no more frequently than once every 2 weeks. For H-ARS: two doses of up to 20 mg subcutaneously no more frequently than 1 week apart. Requests for dosing outside the established policy dosing are reviewed case by case by a clinician.

    Preferred-Product Requirements

    StepPlanRequired prior trial(s)Documentation
    1Employer PlansRolvedon and one pegfilgrastim product for the cancer indicationRequired
    StepPlanRequired prior trial(s)Documentation
    1Individual and Family PlansOne pegfilgrastim product for the cancer indicationRequired

    Quantity and Dosing Limits

    Ryzneuta cancer-indication quantity limit
    Maximum doseUp to 20 mg
    RouteSubcutaneous injection
    Minimum intervalNo more frequently than once every 2 weeks
    Ryzneuta H-ARS quantity limit
    Maximum quantityTwo doses per course
    Dose amountUp to 20 mg per dose
    Minimum intervalNo more frequently than 1 week apart
    Policy Summary
    PayerCigna
    PolicyColony Stimulating Factors - Ryzneuta
    Policy CodePolicy IP0745
    Change TypeNo material clinical or coverage change
    Effective DateNovember 15, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document that the applicable clinical criteria and dosing requirements are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and Denial RisksBackgroundDefinitionsInitial Therapy CriteriaContinuation TherapyPreferred-Product RequirementsQuantity and Dosing Limits
    Risk-factor examples
    Examples include prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, poor performance status, or HIV infection with low CD4 counts
    Age requirement
    Minimum ageAt least 18 years of age
    Cancer indicationThe patient must be at least 18 years of age for approval of the cancer indication
    H-ARS indicationThe patient must be at least 18 years of age for approval of the H-ARS indication
    Liver dysfunction risk factor
    Bilirubin thresholdBilirubin greater than 2.0 mg/dL
    Risk-factor categoryLiver dysfunction is a risk factor for febrile neutropenia
    Applicable pathwayMay support coverage when chemotherapy-associated febrile neutropenia risk is less than 20% and at least one risk factor is present
    Renal dysfunction risk factor
    Creatinine-clearance thresholdCreatinine clearance less than 50 mL/min
    Risk-factor categoryRenal dysfunction is a risk factor for febrile neutropenia
    Applicable pathwayMay support coverage when chemotherapy-associated febrile neutropenia risk is less than 20% and at least one risk factor is present
    Chemotherapy-indication dosing
    Maximum doseUp to 20 mg
    RouteSubcutaneous injection
    Minimum intervalNo more frequently than once every 2 weeks
    H-ARS dosing
    Number of dosesTwo doses
    Dose amountUp to 20 mg per dose
    Route and intervalBy subcutaneous injection, no more frequently than 1 week apart

    Unsupported block type: denial_risk

    Step Therapy

    Employer Plan Step Therapy

    For Employer Plans, Ryzneuta coverage for cancer in a patient receiving myelosuppressive chemotherapy requires documented trial history with both Rolvedon and one pegfilgrastim product.

    • The patient must have tried Rolvedon.
    • The patient must have tried one pegfilgrastim product.
    • Pegfilgrastim products include Neulasta, Armlupeg, Fulphila, Fylnetra, Nyvepria, Udenyca, Stimufend, and Ziextenzo.
    Step Therapy

    Individual and Family Plan Step Therapy

    For Individual and Family Plans, Ryzneuta coverage for cancer in a patient receiving myelosuppressive chemotherapy requires a trial of one pegfilgrastim product.

    • The patient must have tried one pegfilgrastim product.
    • Pegfilgrastim products include Neulasta, Armlupeg, Fulphila, Fylnetra, Nyvepria, Udenyca, Stimufend, and Ziextenzo.
    Documentation Required

    Clinical Documentation Required

    Submit patient-specific clinical documentation when the criteria identify documentation as required. Documentation may include chart notes, laboratory tests, medical test results, claims records, and other relevant information, and every document must include patient-specific identifying information.

    • Document the diagnosis and applicable covered indication.
    • Document age, chemotherapy regimen and febrile-neutropenia risk or relevant prior neutropenic complication, as applicable.
    • Document specialist prescribing or consultation and the requested dose and schedule.
    • Document required preferred-product trials and treatment response, intolerance, or other relevant history.
    Documentation Required

    Employer Plan Preferred-Product History

    For Employer Plans, documentation must substantiate trials of both required preferred-product categories before Ryzneuta is approved for the cancer indication.

    • Provide records confirming a trial of Rolvedon.
    • Provide records confirming a trial of one pegfilgrastim product.
    • Claims records, chart notes, or other patient-specific treatment records may be used when they identify the patient and support the trial history.
    Documentation Required

    Individual and Family Plan Preferred-Product History

    For Individual and Family Plans, documentation must substantiate a trial of one pegfilgrastim product before Ryzneuta is approved for the cancer indication.

    • Provide patient-specific records confirming the pegfilgrastim trial.
    • Acceptable supporting records may include chart notes, claims records, or other documentation showing the product and treatment history.
    Denial Risk

    Noncovered Uses

    Ryzneuta for uses other than the covered indications and criteria is considered not medically necessary. The policy specifically identifies peripheral blood progenitor cell collection and therapy as not covered because Ryzneuta is not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

    • Do not submit Ryzneuta for PBPC mobilization or collection for hematopoietic stem cell transplantation.
    • The list of noncovered uses may be updated as new published data become available.
    Billing Rule

    Covered Coding Must Be Present and Applicable

    Claims may be denied as not covered when they are submitted without applicable covered procedure and diagnosis codes, or when the codes do not apply to the service or condition. Providers must use the most appropriate codes that are effective on the submission date.

    • Confirm that the billed diagnosis and procedure codes are covered under the applicable policy.
    • Deleted or not-yet-effective codes may not be eligible for reimbursement.
    • The policy's code list may not be all-inclusive.
    Denial Risk

    Criteria Not Met May Result in Denial

    Coverage may be denied when the patient does not meet the applicable age, indication, specialist-prescribing, clinical-risk, preferred-product, or dosing requirements. Approval depends on satisfying all required criteria for the requested indication.

    • Cancer indication: the patient must be at least 18 years old and meet an approved febrile-neutropenia risk or prior neutropenic-complication pathway.
    • Acute radiation syndrome: the patient must be at least 18 years old and receive care from a physician with relevant expertise.
    • The required oncologist or hematologist involvement and plan-specific preferred-product history must be documented.
    • Requests exceeding policy dosing limits require case-by-case clinical review.
    A radiologic or nuclear incident
  1. Intermediate-risk regimen with risk factor

    • The patient is receiving myelosuppressive anticancer medications associated with a febrile-neutropenia risk below 20% based on the chemotherapy regimen.Risk <20% based on the chemotherapy regimen
    • The patient has at least one risk factor for febrile neutropenia according to the prescriber.

      Examples include age >65 years receiving full chemotherapy dose intensity, prior chemotherapy or radiation therapy, persistent neutropenia, bone marrow involvement by tumor, recent surgery or open wounds, bilirubin >2.0 mg/dL, creatinine clearance <50 mL/min, poor performance status, or HIV infection with low CD4 counts.

  2. Prior neutropenic complication

    • The patient had a neutropenic complication during a prior chemotherapy cycle without prophylaxis with a colony-stimulating factor.
    • A reduced dose or frequency of chemotherapy may compromise treatment outcome.
  3. Specialist prescriber

    • Ryzneuta is prescribed by or in consultation with an oncologist or hematologist.
  4. Preferred product criteria

    • Applicable plan-specific preferred product requirements are met.

      Employer Plans require trials of Rolvedon and one pegfilgrastim product. Individual and Family Plans require a trial of one pegfilgrastim product.

  5. Dosing

    • Ryzneuta is administered by subcutaneous injection at a dose of no more than 20 mg, no more frequently than once every 2 weeks.Up to 20 mg subcutaneously no more frequently than once every 2 weeks
  6. Hematopoietic Acute Radiation Syndrome

    Approve for 1 month when both H-ARS criteria and dosing requirements are met.

    Initial H-ARS therapy approval

    • The patient is at least 18 years of age and has hematopoietic acute radiation syndrome.≥18 years
    • Ryzneuta is prescribed by or in consultation with a physician who has expertise in treating acute radiation syndrome.
    • Dosing

      • Ryzneuta is administered as two doses by subcutaneous injection, with each dose no more than 20 mg and the doses no more frequently than 1 week apart.Two doses of up to 20 mg subcutaneously no more frequently than 1 week apart